NuCana plc ADR is a clinical-stage biopharmaceutical company focused on developing cancer medicines using its proprietary ProTide technology. The company’s current work centers on transforming established chemotherapy agents and nucleoside analogs into new therapies designed for oncology use. Its pipeline includes investigational programs aimed at addressing solid tumors and improving how anti-cancer compounds are delivered inside cancer cells. NuCana plc ADR represents the company’s U.S.-traded depositary shares, providing market access to an oncology-focused biotechnology business based in Edinburgh, United Kingdom. In the financial markets, the asset is followed for its drug development pipeline, clinical progress, and broader positioning within the biotechnology sector.
Website3 Lochside Way
Edinburgh, EH12 9DT
United Kingdom
Investors talking about NCNA also mention
What share of all stock conversation is about NCNA?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% +0 | 0% 0 | 0% -0.01 |
Of the messages about NCNA that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 66.67% +16.67 | 85.77% +4.83 | ||
| Bearish | — | — | 33.33% -16.67 | 14.23% -4.83 |
Of the messages about NCNA that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | — | 53.78% | ||
| Technical Analysis | — | — | — | 43.41% | ||
| Analysts | — | — | — | 1.33% | ||
| Controversies | — | — | — | 1.19% | ||
| Earnings | — | — | — | 0.3% | ||
| Macro | — | — | — | 0% |
Of the messages about NCNA, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 100% | 90.91% | 61.4% | ||
| Newcomers | 0% | 0% | 9.09% | 38.6% |